FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564408362> ?p ?o ?g. }

• W2564408362 endingPage "417" @default.
• W2564408362 startingPage "411" @default.
• W2564408362 abstract "Rationale and Objectives The BI-RADS Atlas 5th Edition includes screening breast magnetic resonance imaging (MRI) outcome benchmarks. However, the metrics are from expert practices and clinical trials of women with hereditary breast cancer predispositions, and it is unknown if they are appropriate for routine practice. We evaluated screening breast MRI audit outcomes in routine practice across a spectrum of elevated risk patients. Materials and Methods This Institutional Review Board-approved, Health Insurance Portability and Accountability Act-compliant retrospective study included all consecutive screening breast MRI examinations from July 1, 2010 to June 30, 2013. Examination indications were categorized as gene mutation carrier (GMC), personal history (PH) breast cancer, family history (FH) breast cancer, chest radiation, and atypia/lobular carcinoma in situ (LCIS). Outcomes were determined by pathology and/or ≥12 months clinical and/or imaging follow-up. We calculated abnormal interpretation rate (AIR), cancer detection rate (CDR), positive predictive value of recommendation for tissue diagnosis (PPV2) and biopsy performed (PPV3), and median size and percentage of node-negative invasive cancers. Results Eight hundred and sixty examinations were performed in 566 patients with a mean age of 47 years. Indications were 367 of 860 (42.7%) FH, 365 of 860 (42.4%) PH, 106 of 860 (12.3%) GMC, 14 of 860 (1.6%) chest radiation, and 8 of 22 (0.9%) atypia/LCIS. The AIR was 134 of 860 (15.6%). Nineteen cancers were identified (13 invasive, 4 DCIS, two lymph nodes), resulting in CDR of 19 of 860 (22.1 per 1000), PPV2 of 19 of 88 (21.6%), and PPV3 of 19 of 80 (23.8%). Of 13 invasive breast cancers, median size was 10 mm, and 8 of 13 were node negative (61.5%). Conclusions Performance outcomes of screening breast MRI in routine clinical practice across a spectrum of elevated risk patients met the American College of Radiology Breast Imaging Reporting and Data System benchmarks, supporting broad application of these metrics. The indication of a personal history of treated breast cancer accounted for a large proportion (42%) of our screening examinations, with breast MRI performance in this population at least comparable to that of other screening indications. The BI-RADS Atlas 5th Edition includes screening breast magnetic resonance imaging (MRI) outcome benchmarks. However, the metrics are from expert practices and clinical trials of women with hereditary breast cancer predispositions, and it is unknown if they are appropriate for routine practice. We evaluated screening breast MRI audit outcomes in routine practice across a spectrum of elevated risk patients. This Institutional Review Board-approved, Health Insurance Portability and Accountability Act-compliant retrospective study included all consecutive screening breast MRI examinations from July 1, 2010 to June 30, 2013. Examination indications were categorized as gene mutation carrier (GMC), personal history (PH) breast cancer, family history (FH) breast cancer, chest radiation, and atypia/lobular carcinoma in situ (LCIS). Outcomes were determined by pathology and/or ≥12 months clinical and/or imaging follow-up. We calculated abnormal interpretation rate (AIR), cancer detection rate (CDR), positive predictive value of recommendation for tissue diagnosis (PPV2) and biopsy performed (PPV3), and median size and percentage of node-negative invasive cancers. Eight hundred and sixty examinations were performed in 566 patients with a mean age of 47 years. Indications were 367 of 860 (42.7%) FH, 365 of 860 (42.4%) PH, 106 of 860 (12.3%) GMC, 14 of 860 (1.6%) chest radiation, and 8 of 22 (0.9%) atypia/LCIS. The AIR was 134 of 860 (15.6%). Nineteen cancers were identified (13 invasive, 4 DCIS, two lymph nodes), resulting in CDR of 19 of 860 (22.1 per 1000), PPV2 of 19 of 88 (21.6%), and PPV3 of 19 of 80 (23.8%). Of 13 invasive breast cancers, median size was 10 mm, and 8 of 13 were node negative (61.5%). Performance outcomes of screening breast MRI in routine clinical practice across a spectrum of elevated risk patients met the American College of Radiology Breast Imaging Reporting and Data System benchmarks, supporting broad application of these metrics. The indication of a personal history of treated breast cancer accounted for a large proportion (42%) of our screening examinations, with breast MRI performance in this population at least comparable to that of other screening indications." @default.
• W2564408362 created "2017-01-06" @default.
• W2564408362 creator A5004905747 @default.
• W2564408362 creator A5022574816 @default.
• W2564408362 creator A5035217623 @default.
• W2564408362 creator A5046169500 @default.
• W2564408362 creator A5060361898 @default.
• W2564408362 creator A5075573580 @default.
• W2564408362 creator A5084471958 @default.
• W2564408362 creator A5087358853 @default.
• W2564408362 date "2017-04-01" @default.
• W2564408362 modified "2023-10-03" @default.
• W2564408362 title "Screening Breast MRI Outcomes in Routine Clinical Practice" @default.
• W2564408362 cites W1534216133 @default.
• W2564408362 cites W1974545011 @default.
• W2564408362 cites W1983831437 @default.
• W2564408362 cites W1993418832 @default.
• W2564408362 cites W2005608675 @default.
• W2564408362 cites W2012422096 @default.
• W2564408362 cites W2030617046 @default.
• W2564408362 cites W2037737757 @default.
• W2564408362 cites W2046173640 @default.
• W2564408362 cites W2062069575 @default.
• W2564408362 cites W2080726086 @default.
• W2564408362 cites W2084297683 @default.
• W2564408362 cites W2088047356 @default.
• W2564408362 cites W2105213027 @default.
• W2564408362 cites W2105722841 @default.
• W2564408362 cites W2111466455 @default.
• W2564408362 cites W2115947304 @default.
• W2564408362 cites W2121935084 @default.
• W2564408362 cites W2133591380 @default.
• W2564408362 cites W2143559692 @default.
• W2564408362 cites W2150064779 @default.
• W2564408362 cites W2151744107 @default.
• W2564408362 cites W2164900614 @default.
• W2564408362 cites W2168140453 @default.
• W2564408362 cites W2172296348 @default.
• W2564408362 cites W2237958539 @default.
• W2564408362 cites W2361503148 @default.
• W2564408362 doi "https://doi.org/10.1016/j.acra.2016.10.014" @default.
• W2564408362 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5339052" @default.
• W2564408362 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27986508" @default.
• W2564408362 hasPublicationYear "2017" @default.
• W2564408362 type Work @default.
• W2564408362 sameAs 2564408362 @default.
• W2564408362 citedByCount "31" @default.
• W2564408362 countsByYear W25644083622017 @default.
• W2564408362 countsByYear W25644083622018 @default.
• W2564408362 countsByYear W25644083622019 @default.
• W2564408362 countsByYear W25644083622020 @default.
• W2564408362 countsByYear W25644083622021 @default.
• W2564408362 countsByYear W25644083622022 @default.
• W2564408362 countsByYear W25644083622023 @default.
• W2564408362 crossrefType "journal-article" @default.
• W2564408362 hasAuthorship W2564408362A5004905747 @default.
• W2564408362 hasAuthorship W2564408362A5022574816 @default.
• W2564408362 hasAuthorship W2564408362A5035217623 @default.
• W2564408362 hasAuthorship W2564408362A5046169500 @default.
• W2564408362 hasAuthorship W2564408362A5060361898 @default.
• W2564408362 hasAuthorship W2564408362A5075573580 @default.
• W2564408362 hasAuthorship W2564408362A5084471958 @default.
• W2564408362 hasAuthorship W2564408362A5087358853 @default.
• W2564408362 hasBestOaLocation W25644083622 @default.
• W2564408362 hasConcept C121608353 @default.
• W2564408362 hasConcept C126322002 @default.
• W2564408362 hasConcept C126838900 @default.
• W2564408362 hasConcept C141071460 @default.
• W2564408362 hasConcept C142724271 @default.
• W2564408362 hasConcept C2777106319 @default.
• W2564408362 hasConcept C2777111374 @default.
• W2564408362 hasConcept C2777432617 @default.
• W2564408362 hasConcept C2780472235 @default.
• W2564408362 hasConcept C2781179581 @default.
• W2564408362 hasConcept C2781283455 @default.
• W2564408362 hasConcept C530470458 @default.
• W2564408362 hasConcept C71924100 @default.
• W2564408362 hasConceptScore W2564408362C121608353 @default.
• W2564408362 hasConceptScore W2564408362C126322002 @default.
• W2564408362 hasConceptScore W2564408362C126838900 @default.
• W2564408362 hasConceptScore W2564408362C141071460 @default.
• W2564408362 hasConceptScore W2564408362C142724271 @default.
• W2564408362 hasConceptScore W2564408362C2777106319 @default.
• W2564408362 hasConceptScore W2564408362C2777111374 @default.
• W2564408362 hasConceptScore W2564408362C2777432617 @default.
• W2564408362 hasConceptScore W2564408362C2780472235 @default.
• W2564408362 hasConceptScore W2564408362C2781179581 @default.
• W2564408362 hasConceptScore W2564408362C2781283455 @default.
• W2564408362 hasConceptScore W2564408362C530470458 @default.
• W2564408362 hasConceptScore W2564408362C71924100 @default.
• W2564408362 hasFunder F4320308932 @default.
• W2564408362 hasIssue "4" @default.
• W2564408362 hasLocation W25644083621 @default.
• W2564408362 hasLocation W25644083622 @default.
• W2564408362 hasLocation W25644083623 @default.
• W2564408362 hasLocation W25644083624 @default.
• W2564408362 hasOpenAccess W2564408362 @default.
• W2564408362 hasPrimaryLocation W25644083621 @default.

• next